Search research articles
Contact Us
Filters
Showing results (111-120 of 165) with videos related to
Page
of 17
Sort By:
Journal of Thrombosis and Thrombolysis
|
November 14, 2013
Comparison of cost-effectiveness of anticoagulation with dabigatran, rivaroxaban and apixaban in patients with non-valvular atrial fibrillation across countries
Martin Krejczy, Job Harenberg, Svetlana Marx, et al.
Seminars in Thrombosis and Hemostasis
|
February 16, 2015
Patients' serum and urine as easily accessible samples for the measurement of non-vitamin K antagonist oral anticoagulants
Job Harenberg, Shanshan Du, Sandra Krämer, et al.
Diabetes
|
July 30, 2002
Glucose increases endothelial-dependent superoxide formation in coronary arteries by NAD(P)H oxidase activation: attenuation by the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor atorvastatin
Michael Christ, Johann Bauersachs, Claudia Liebetrau, et al.
Therapeutic Drug Monitoring
|
December 20, 2014
Measurement of Non-Vitamin K Antagonist Oral Anticoagulants in Patient Plasma Using Heptest-STAT Coagulation Method
Shanshan Du, Job Harenberg, Sandra Krämer, et al.
Biomed Research International
|
April 9, 2015
Cost-effectiveness of anticoagulation in patients with nonvalvular atrial fibrillation with edoxaban compared to warfarin in Germany
Martin Krejczy, Job Harenberg, Martin Wehling, et al.
Molecular and Cellular Endocrinology
|
February 17, 2005
Enhancement of beta-adrenergic cAMP-signaling by the mineralocorticoid receptor
Michael Christ, Martin Wehling, Elke Kirsch, et al.
European Journal of Endocrinology
|
March 3, 2010
Position paper: Rapid responses to steroids: current status and future prospects
Alexandra Wendler, Elisabetta Baldi, Brian J Harvey, et al.
Drugs - Real World Outcomes
|
March 17, 2022
The Sex-Specific Impact of the FORTA (Fit-fOR-The-Aged) List on Medication Quality and Clinical Endpoints in Older Hospitalized Patients: Secondary Analysis of a Randomized Controlled Trial
Ann-Kathrin Schmitt, Christel Weiss, Heinrich Burkhardt, et al.
Thrombosis and Haemostasis
|
January 23, 2015
Chromogenic assays for measurement of rivaroxaban from EDTA anticoagulated plasma samples
Shanshan Du, Sandra Krämer, Christina Giese, et al.
Clinical Chemistry and Laboratory Medicine
|
July 14, 2015
Measurement of dabigatran, rivaroxaban and apixaban in samples of plasma, serum and urine, under real life conditions. An international study
Job Harenberg, Shanshan Du, Martin Wehling, et al.
Page
of 17
Search research articles
Search
Showing results (111-120 of 165) with videos related to
Sort By:
Page
of 17
Journal of Thrombosis and Thrombolysis
|
November 14, 2013
Comparison of cost-effectiveness of anticoagulation with dabigatran, rivaroxaban and apixaban in patients with non-valvular atrial fibrillation across countries
Martin Krejczy, Job Harenberg, Svetlana Marx, et al.
Seminars in Thrombosis and Hemostasis
|
February 16, 2015
Patients' serum and urine as easily accessible samples for the measurement of non-vitamin K antagonist oral anticoagulants
Job Harenberg, Shanshan Du, Sandra Krämer, et al.
Diabetes
|
July 30, 2002
Glucose increases endothelial-dependent superoxide formation in coronary arteries by NAD(P)H oxidase activation: attenuation by the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor atorvastatin
Michael Christ, Johann Bauersachs, Claudia Liebetrau, et al.
Therapeutic Drug Monitoring
|
December 20, 2014
Measurement of Non-Vitamin K Antagonist Oral Anticoagulants in Patient Plasma Using Heptest-STAT Coagulation Method
Shanshan Du, Job Harenberg, Sandra Krämer, et al.
Biomed Research International
|
April 9, 2015
Cost-effectiveness of anticoagulation in patients with nonvalvular atrial fibrillation with edoxaban compared to warfarin in Germany
Martin Krejczy, Job Harenberg, Martin Wehling, et al.
Molecular and Cellular Endocrinology
|
February 17, 2005
Enhancement of beta-adrenergic cAMP-signaling by the mineralocorticoid receptor
Michael Christ, Martin Wehling, Elke Kirsch, et al.
European Journal of Endocrinology
|
March 3, 2010
Position paper: Rapid responses to steroids: current status and future prospects
Alexandra Wendler, Elisabetta Baldi, Brian J Harvey, et al.
Drugs - Real World Outcomes
|
March 17, 2022
The Sex-Specific Impact of the FORTA (Fit-fOR-The-Aged) List on Medication Quality and Clinical Endpoints in Older Hospitalized Patients: Secondary Analysis of a Randomized Controlled Trial
Ann-Kathrin Schmitt, Christel Weiss, Heinrich Burkhardt, et al.
Thrombosis and Haemostasis
|
January 23, 2015
Chromogenic assays for measurement of rivaroxaban from EDTA anticoagulated plasma samples
Shanshan Du, Sandra Krämer, Christina Giese, et al.
Clinical Chemistry and Laboratory Medicine
|
July 14, 2015
Measurement of dabigatran, rivaroxaban and apixaban in samples of plasma, serum and urine, under real life conditions. An international study
Job Harenberg, Shanshan Du, Martin Wehling, et al.
Page
of 17